Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • The authors reply:
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Letter to the EditorHepatology Open Access | 10.1172/JCI161425

Concerns about the inverse relationship between baseline HBV DNA and on-treatment hepatocellular carcinoma risk. Reply.

Won-Mook Choi and Young-Suk Lim

Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Address correspondence to: Young-Suk Lim, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea. Phone: 82.02.3010.5933; Email: limys@amc.seoul.kr.

Find articles by Choi, W. in: JCI | PubMed | Google Scholar |

Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Address correspondence to: Young-Suk Lim, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea. Phone: 82.02.3010.5933; Email: limys@amc.seoul.kr.

Find articles by Lim, Y. in: JCI | PubMed | Google Scholar |

Published August 1, 2022 - More info

Published in Volume 132, Issue 15 on August 1, 2022
J Clin Invest. 2022;132(15):e161425. https://doi.org/10.1172/JCI161425.
© 2022 Choi et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published August 1, 2022 - Version history
View PDF

Related article:

Concerns about the inverse relationship between baseline HBV DNA and on-treatment hepatocellular carcinoma risk
Shi Liu, … , Yongyin Li, Jian Sun
Shi Liu, … , Yongyin Li, Jian Sun
Letter to the Editor Hepatology

Concerns about the inverse relationship between baseline HBV DNA and on-treatment hepatocellular carcinoma risk

  • Text
  • PDF
Abstract

Authors

Shi Liu, Yongyin Li, Jian Sun

×

The authors reply:

We appreciate the letter from Liu et al. regarding our study (1).

First of all, the 2457 patients consecutively evaluated for eligibility in our study do not represent the total number of patients with chronic hepatitis B (CHB) during the ten-year enrollment period. Rather, those numbers were the remnants after excluding patients with cirrhosis, HBeAg negativity, previous history of malignancy or immunosuppressive agents, and follow-up duration of less than one year. We completely agree with and welcome validation of our results using independent cohorts with a larger sample size.

Second, we agree with the importance of other confounders, such as obesity, diabetes, drinking, and treatment response, in evaluating the risk of hepatocellular carcinoma (HCC) in patients with CHB. The result was consistent when the diabetes was further adjusted in 72.7% of the patients to whom the presence or absence of diabetes could be traced. Drinking is mostly based on self-reported data, which are prone to recall bias and cannot be fully guaranteed for data completeness and accuracy. Thus, we did not include drinking in the adjustment because of these possible biases. Obesity could not be adjusted any further because there were a lot of missing data in the study. However, a confounding factor that would affect the outcome must be unequally distributed among the groups being compared (2). In this case, there was no evidence from previous studies, and it is unlikely that the proportion of patients with obesity would be unequally distributed across the groups stratified by baseline HBV DNA levels. We did not include biochemical or virological response, since the analysis was based on the intention-to-treat principle.

Finally, subsequent data from the REVEAL cohort also showed a lower risk of HCC in patients with HBV DNA levels of greater than 107 copies/mL than those with HBV DNA levels between 106 and 107 copies/mL (3, 4), in line with our study (5). A decreasing but considerable viral load of more than 5 log10 IU/mL may indicate the clonal emergence of hepatocytes that produce less virus. In addition, moderate serum HBV DNA levels were a risk factor for hepatic inflammation despite normal alanine transaminase levels and the absence of significant fibrosis (6), further contributing to the clonal hepatocyte repopulation. Hepatocarcinogenesis following the clonal expansion of hepatocytes and integration of HBV DNA into the host genome even with no significant fibrosis could be underway, which cannot be fully reversed by belated antiviral treatment. Moreover, considering the potent long-term efficacy and safety of current antiviral treatments that have a high genetic barrier to resistance and also a decrease in cost with the wide availability of generic drugs, antiviral treatment in immune-tolerant patients is cost-effective compared with delaying the treatment following the current clinical practice guidelines (7). Thus, we believe that early initiation of antiviral treatment may maintain the lowest risk of HCC in HBeAg-positive, noncirrhotic, adult patients with CHB, contributing to a decrease in global HCC incidence and HCC-related mortality.

Footnotes

Conflict of interest: YSM is an advisory board member of Gilead Sciences and receives investigator-initiated research funding from this institution.

Reference information: J Clin Invest. 2022;132(15):e161425. https://doi.org/10.1172/JCI161425.

See the related article at Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B .

See the related reply to the Letter to the Editor at Concerns about the inverse relationship between baseline HBV DNA and on-treatment hepatocellular carcinoma risk.

References
  1. Choi WM, et al. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B. J Clin Invest. 2022;132(10):154833.
    View this article via: JCI PubMed Google Scholar
  2. Jager KJ, et al. Confounding: what it is and how to deal with it. Kidney Int. 2008;73(3):256–260.
    View this article via: CrossRef PubMed Google Scholar
  3. Yang HI, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12(6):568–574.
    View this article via: CrossRef PubMed Google Scholar
  4. Chen CF, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology. 2011;141(4):1240–1248.
    View this article via: CrossRef PubMed Google Scholar
  5. Kim GA, et al. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther. 2020;51(11):1169–1179.
    View this article via: CrossRef PubMed Google Scholar
  6. Liu J, et al. Presence of liver inflammation in Asian patients with chronic hepatitis B with normal ALT and detectable HBV DNA in absence of liver fibrosis. Hepatol Commun. 2022;6(4):855–866.
    View this article via: CrossRef PubMed Google Scholar
  7. Kim HL, et al. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B. Gut. 2021;70(11):2172–2182.
    View this article via: CrossRef PubMed Google Scholar
Version history
  • Version 1 (August 1, 2022): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • The authors reply:
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts